Annual CFF
-$711.00 M
+$873.50 M+55.13%
31 December 2023
Summary:
Edwards Lifesciences annual cash flow from financing activities is currently -$711.00 million, with the most recent change of +$873.50 million (+55.13%) on 31 December 2023. During the last 3 years, it has fallen by -$224.10 million (-46.03%). EW annual CFF is now -2137.25% below its all-time high of $34.90 million, reached on 31 December 2013.EW Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$976.70 M
-$880.10 M-911.08%
30 September 2024
Summary:
Edwards Lifesciences quarterly cash flow from financing activities is currently -$976.70 million, with the most recent change of -$880.10 million (-911.08%) on 30 September 2024. Over the past year, it has dropped by -$833.40 million (-581.58%). EW quarterly CFF is now -870.27% below its all-time high of $126.80 million, reached on 30 June 2017.EW Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$1.42 B
-$833.40 M-140.92%
30 September 2024
Summary:
Edwards Lifesciences TTM cash flow from financing activities is currently -$1.42 billion, with the most recent change of -$833.40 million (-140.92%) on 30 September 2024. Over the past year, it has dropped by -$288.60 million (-25.40%). EW TTM CFF is now -4182.52% below its all-time high of $34.90 million, reached on 31 December 2013.EW TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EW Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +55.1% | -581.6% | -25.4% |
| 3 y3 years | -46.0% | -2604.4% | -463.4% |
| 5 y5 years | +35.4% | -2939.2% | -42.9% |
EW Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.5% | +55.1% | -1683.0% | at low | -463.4% | +10.1% |
| 5 y | 5 years | -515.0% | +55.1% | -1683.0% | at low | -1132.5% | +10.1% |
| alltime | all time | -2137.3% | +55.1% | -870.3% | at low | -4182.5% | +10.1% |
Edwards Lifesciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$976.70 M(+911.1%) | -$1.42 B(+140.9%) |
| June 2024 | - | -$96.60 M(-256.6%) | -$591.40 M(+33.6%) |
| Mar 2024 | - | $61.70 M(-114.9%) | -$442.70 M(-37.7%) |
| Dec 2023 | -$711.00 M(-55.1%) | -$413.20 M(+188.3%) | -$711.00 M(-37.4%) |
| Sept 2023 | - | -$143.30 M(-375.0%) | -$1.14 B(+6.9%) |
| June 2023 | - | $52.10 M(-125.2%) | -$1.06 B(-25.3%) |
| Mar 2023 | - | -$206.60 M(-75.4%) | -$1.42 B(-10.2%) |
| Dec 2022 | -$1.58 B(+344.7%) | -$838.40 M(+1099.4%) | -$1.58 B(+96.1%) |
| Sept 2022 | - | -$69.90 M(-77.3%) | -$808.10 M(+15.6%) |
| June 2022 | - | -$308.10 M(-16.3%) | -$699.20 M(+55.3%) |
| Mar 2022 | - | -$368.10 M(+493.7%) | -$450.10 M(+26.3%) |
| Dec 2021 | -$356.30 M(-26.8%) | -$62.00 M(-259.0%) | -$356.30 M(+40.9%) |
| Sept 2021 | - | $39.00 M(-166.1%) | -$252.90 M(-1.9%) |
| June 2021 | - | -$59.00 M(-78.5%) | -$257.90 M(+47.5%) |
| Mar 2021 | - | -$274.30 M(-762.6%) | -$174.80 M(-64.1%) |
| Dec 2020 | -$486.90 M(+321.2%) | $41.40 M(+21.8%) | -$486.90 M(-0.9%) |
| Sept 2020 | - | $34.00 M(+41.1%) | -$491.30 M(+0.1%) |
| June 2020 | - | $24.10 M(-104.1%) | -$490.90 M(-34.2%) |
| Mar 2020 | - | -$586.40 M(-1684.9%) | -$746.40 M(+545.7%) |
| Dec 2019 | -$115.60 M(-89.5%) | $37.00 M(+7.6%) | -$115.60 M(-88.4%) |
| Sept 2019 | - | $34.40 M(-114.9%) | -$997.30 M(-8.4%) |
| June 2019 | - | -$231.40 M(-621.2%) | -$1.09 B(-0.8%) |
| Mar 2019 | - | $44.40 M(-105.3%) | -$1.10 B(-0.3%) |
| Dec 2018 | -$1.10 B(+132.7%) | -$844.70 M(+1389.8%) | -$1.10 B(+126.8%) |
| Sept 2018 | - | -$56.70 M(-76.4%) | -$485.50 M(+18.8%) |
| June 2018 | - | -$240.70 M(-688.5%) | -$408.50 M(+896.3%) |
| Mar 2018 | - | $40.90 M(-117.9%) | -$41.00 M(-91.3%) |
| Dec 2017 | -$473.20 M(+76.2%) | -$229.00 M(-1228.1%) | -$473.20 M(+97.9%) |
| Sept 2017 | - | $20.30 M(-84.0%) | -$239.10 M(+22.2%) |
| June 2017 | - | $126.80 M(-132.4%) | -$195.60 M(-32.7%) |
| Mar 2017 | - | -$391.30 M(-7772.5%) | -$290.70 M(+8.3%) |
| Dec 2016 | -$268.50 M(+69.3%) | $5.10 M(-92.0%) | -$268.50 M(-19.4%) |
| Sept 2016 | - | $63.80 M(+101.3%) | -$333.30 M(-10.8%) |
| June 2016 | - | $31.70 M(-108.6%) | -$373.50 M(-18.1%) |
| Mar 2016 | - | -$369.10 M(+518.3%) | -$455.80 M(+187.4%) |
| Dec 2015 | -$158.60 M(+3.7%) | -$59.70 M(-353.0%) | -$158.60 M(+199.2%) |
| Sept 2015 | - | $23.60 M(-146.6%) | -$53.00 M(+90.0%) |
| June 2015 | - | -$50.60 M(-29.6%) | -$27.90 M(-65.6%) |
| Mar 2015 | - | -$71.90 M(-256.6%) | -$81.10 M(-47.0%) |
| Dec 2014 | -$153.00 M(-538.4%) | $45.90 M(-5.7%) | -$153.00 M(+29.2%) |
| Sept 2014 | - | $48.70 M(-146.9%) | -$118.40 M(+20.2%) |
| June 2014 | - | -$103.80 M(-27.8%) | -$98.50 M(+17.3%) |
| Mar 2014 | - | -$143.80 M(-278.6%) | -$84.00 M(-340.7%) |
| Dec 2013 | $34.90 M(-122.4%) | $80.50 M(+17.3%) | $34.90 M(-118.1%) |
| Sept 2013 | - | $68.60 M(-176.8%) | -$192.50 M(-26.4%) |
| June 2013 | - | -$89.30 M(+258.6%) | -$261.60 M(+47.5%) |
| Mar 2013 | - | -$24.90 M(-83.0%) | -$177.40 M(+14.0%) |
| Dec 2012 | -$155.60 M | -$146.90 M(>+9900.0%) | -$155.60 M(+149.8%) |
| Sept 2012 | - | -$500.00 K(-90.2%) | -$62.30 M(-60.8%) |
| June 2012 | - | -$5.10 M(+64.5%) | -$159.00 M(-19.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$3.10 M(-94.2%) | -$197.80 M(+46.3%) |
| Dec 2011 | -$135.20 M(+30.1%) | -$53.60 M(-44.9%) | -$135.20 M(+25.0%) |
| Sept 2011 | - | -$97.20 M(+121.4%) | -$108.20 M(+60.1%) |
| June 2011 | - | -$43.90 M(-173.8%) | -$67.60 M(+77.9%) |
| Mar 2011 | - | $59.50 M(-323.7%) | -$38.00 M(-63.4%) |
| Dec 2010 | -$103.90 M(+13.2%) | -$26.60 M(-53.0%) | -$103.90 M(+41.6%) |
| Sept 2010 | - | -$56.60 M(+295.8%) | -$73.40 M(+70.3%) |
| June 2010 | - | -$14.30 M(+123.4%) | -$43.10 M(-2.7%) |
| Mar 2010 | - | -$6.40 M(-264.1%) | -$44.30 M(-51.7%) |
| Dec 2009 | -$91.80 M(-31.5%) | $3.90 M(-114.8%) | -$91.80 M(-35.0%) |
| Sept 2009 | - | -$26.30 M(+69.7%) | -$141.30 M(+31.1%) |
| June 2009 | - | -$15.50 M(-71.2%) | -$107.80 M(+20.6%) |
| Mar 2009 | - | -$53.90 M(+18.2%) | -$89.40 M(-33.3%) |
| Dec 2008 | -$134.10 M(+24.1%) | -$45.60 M(-733.3%) | -$134.10 M(+25.6%) |
| Sept 2008 | - | $7.20 M(+148.3%) | -$106.80 M(-28.8%) |
| June 2008 | - | $2.90 M(-102.9%) | -$150.10 M(-21.0%) |
| Mar 2008 | - | -$98.60 M(+438.8%) | -$189.90 M(+75.7%) |
| Dec 2007 | -$108.10 M(-44.2%) | -$18.30 M(-49.3%) | -$108.10 M(-11.5%) |
| Sept 2007 | - | -$36.10 M(-2.2%) | -$122.10 M(-16.8%) |
| June 2007 | - | -$36.90 M(+119.6%) | -$146.80 M(-11.2%) |
| Mar 2007 | - | -$16.80 M(-48.0%) | -$165.40 M(-14.6%) |
| Dec 2006 | -$193.60 M(-767.6%) | -$32.30 M(-46.9%) | -$193.60 M(+82.5%) |
| Sept 2006 | - | -$60.80 M(+9.5%) | -$106.10 M(+33.3%) |
| June 2006 | - | -$55.50 M(+23.3%) | -$79.60 M(+339.8%) |
| Mar 2006 | - | -$45.00 M(-181.5%) | -$18.10 M(-162.4%) |
| Dec 2005 | $29.00 M(-241.5%) | $55.20 M(-260.9%) | $29.00 M(-164.2%) |
| Sept 2005 | - | -$34.30 M(-671.7%) | -$45.20 M(-27.6%) |
| June 2005 | - | $6.00 M(+185.7%) | -$62.40 M(-30.7%) |
| Mar 2005 | - | $2.10 M(-111.1%) | -$90.10 M(+339.5%) |
| Dec 2004 | -$20.50 M(-3.3%) | -$19.00 M(-63.1%) | -$20.50 M(-39.9%) |
| Sept 2004 | - | -$51.50 M(+137.3%) | -$34.10 M(+326.3%) |
| June 2004 | - | -$21.70 M(-130.3%) | -$8.00 M(-134.3%) |
| Mar 2004 | - | $71.70 M(-319.9%) | $23.30 M(-209.9%) |
| Dec 2003 | -$21.20 M(-69.5%) | -$32.60 M(+28.3%) | -$21.20 M(-705.7%) |
| Sept 2003 | - | -$25.40 M(-364.6%) | $3.50 M(-40.7%) |
| June 2003 | - | $9.60 M(-64.7%) | $5.90 M(-118.6%) |
| Mar 2003 | - | $27.20 M(-444.3%) | -$31.80 M(-54.2%) |
| Dec 2002 | -$69.50 M(-10.9%) | -$7.90 M(-65.7%) | -$69.50 M(-2.8%) |
| Sept 2002 | - | -$23.00 M(-18.1%) | -$71.50 M(-28.4%) |
| June 2002 | - | -$28.10 M(+167.6%) | -$99.80 M(+1.4%) |
| Mar 2002 | - | -$10.50 M(+6.1%) | -$98.40 M(+26.2%) |
| Dec 2001 | -$78.00 M(+110.8%) | -$9.90 M(-80.7%) | -$78.00 M(-14.9%) |
| Sept 2001 | - | -$51.30 M(+92.1%) | -$91.70 M(+31.4%) |
| June 2001 | - | -$26.70 M(-369.7%) | -$69.80 M(+54.8%) |
| Mar 2001 | - | $9.90 M(-141.9%) | -$45.10 M(+21.9%) |
| Dec 2000 | -$37.00 M(-70.9%) | -$23.60 M(-19.7%) | -$37.00 M(+176.1%) |
| Sept 2000 | - | -$29.40 M(+1370.0%) | -$13.40 M(-183.8%) |
| June 2000 | - | -$2.00 M(-111.1%) | $16.00 M(-11.1%) |
| Mar 2000 | - | $18.00 M | $18.00 M |
| Dec 1999 | -$127.00 M | - | - |
FAQ
- What is Edwards Lifesciences annual cash flow from financing activities?
- What is the all time high annual CFF for Edwards Lifesciences?
- What is Edwards Lifesciences annual CFF year-on-year change?
- What is Edwards Lifesciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Edwards Lifesciences?
- What is Edwards Lifesciences quarterly CFF year-on-year change?
- What is Edwards Lifesciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Edwards Lifesciences?
- What is Edwards Lifesciences TTM CFF year-on-year change?
What is Edwards Lifesciences annual cash flow from financing activities?
The current annual CFF of EW is -$711.00 M
What is the all time high annual CFF for Edwards Lifesciences?
Edwards Lifesciences all-time high annual cash flow from financing activities is $34.90 M
What is Edwards Lifesciences annual CFF year-on-year change?
Over the past year, EW annual cash flow from financing activities has changed by +$873.50 M (+55.13%)
What is Edwards Lifesciences quarterly cash flow from financing activities?
The current quarterly CFF of EW is -$976.70 M
What is the all time high quarterly CFF for Edwards Lifesciences?
Edwards Lifesciences all-time high quarterly cash flow from financing activities is $126.80 M
What is Edwards Lifesciences quarterly CFF year-on-year change?
Over the past year, EW quarterly cash flow from financing activities has changed by -$833.40 M (-581.58%)
What is Edwards Lifesciences TTM cash flow from financing activities?
The current TTM CFF of EW is -$1.42 B
What is the all time high TTM CFF for Edwards Lifesciences?
Edwards Lifesciences all-time high TTM cash flow from financing activities is $34.90 M
What is Edwards Lifesciences TTM CFF year-on-year change?
Over the past year, EW TTM cash flow from financing activities has changed by -$288.60 M (-25.40%)